Physician profile
Joel Wright
NPI 1821187303
$1,394.70
in general payments reported to CMS, 2019-2025
23 companies · $19.19 in 2025
The $19.19 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $178 · 2021: $264 · 2022: $180 · 2023: $199 · 2024: $322 · 2025: $19.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $540.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $205.13 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $169.98 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $121.29 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $105.23 | 2019-2024 | Airsupra, Farxiga |
| Pfizer INC. | $101.90 | 2020-2023 | |
| Sanofi Pasteur INC. | $98.59 | 2021-2023 | |
| Amgen INC. | $86.16 | 2022-2024 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $80.56 | 2022-2024 | |
| Lilly USA, LLC | $68.46 | 2019-2024 | Mounjaro, Zepbound |
| Abbvie INC. | $66.63 | 2021-2024 | |
| Mylan Specialty L.P. | $40.92 | 2020-2023 | Yupelri |
| Exact Sciences Corporation | $35.39 | 2023-2024 | Cologuard Collection Kit |
| Ortho-Clinical Diagnostics, INC. | $34.68 | 2024 | |
| Insulet Corporation | $25.35 | 2024 | Omnipod |
| Beckman Coulter, INC. | $21.65 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $20.59 | 2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $19.50 | 2021 | |
| Cranial Technologies, INC | $19.19 | 2025 | Doc Band |
| Merck Sharp & Dohme LLC | $18.03 | 2024 | Capvaxive, Vaxelis, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.22 | 2024 | Xifaxan, Trulance |
| Vanda Pharmaceuticals INC. | $13.96 | 2020 | |
| Eisai INC. | $13.18 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.